Co-expression of steroid hormone receptors (estrogen receptor α and/or progesterone receptors) and Her2/neu (c-erbB-2) in breast cancer:: Clinical outcome following tamoxifen-based adjuvant therapy

被引:20
作者
Gago, FE
Fanelli, MA
Ciocca, DR
机构
[1] CNR, Inst Expt Med & Biol Cuyo, Lab Oncol, IMBECU CONICET, RA-8555000 Mendoza, Argentina
[2] Argentine Fdn Canc Res, RA-8555000 Mendoza, Argentina
[3] Natl Univ Cuyo, Med Sch, Gynecol Dept, RA-5500 Mendoza, Argentina
关键词
estrogen receptors; progesterone receptors; Her-2/neu; breast cancer; tamoxifen;
D O I
10.1016/j.jsbmb.2005.07.002
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In breast cancer patients, the expression of steroid hormone receptors (HR:ER alpha/PR) appears inversely correlated with Her2/neu (not all reports agree on this negative correlation). Moreover, some but not all studies suggest that HR+/Her2/neu+ patients have a poor response to endocrine therapy, making this special group a matter of debate. In this prospective study we have analyzed the clinical outcome of our HR+/Her2/neu+ patients (n=51) selected from 516 consecutive stages I-II cases, with a follow-up 5-10 years (mean 7.3), treated with standard adjuvant therapy with tamoxifen (TAM) (TAM alone or TAM after chemotherapy). This group was compared with the HR+/Her2/neu- patients (n = 129) treated also with TAM. The tumor biopsies were studied by immunohistochemistry. We found that the association HR+/Her2/neu- was 2.5 times higher than the association HR+/Her2/neu+ (25% versus 9.9%, respectively). Our study also showed that the disease free survival (DFS) of the patients co-expressing HR and Her2/neu was significantly lower than those expressing HR but lacking of Her2/neu (p < 0.001). A similar result was obtained when the overall survival (OS) was evaluated (p = 0.001). All of these patients received hormone therapy with TAM, alone or after chemotherapy. When the analysis was performed in the patients treated with TAM alone, again the expression of Her-2/neu had a negative impact on both the DFS and the OS (P < 0.05). (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:36 / 40
页数:5
相关论文
共 31 条
[1]  
ALSAATI T, 1993, INT J CANCER, V55, P651
[2]   EXPRESSION OF RAS P21, P53 AND C-ERBB-2 IN ADVANCED BREAST-CANCER AND RESPONSE TO FIRST LINE HORMONAL-THERAPY [J].
ARCHER, SG ;
ELIOPOULOS, A ;
SPANDIDOS, D ;
BARNES, D ;
ELLIS, IO ;
BLAMEY, RW ;
NICHOLSON, RI ;
ROBERTSON, JFR .
BRITISH JOURNAL OF CANCER, 1995, 72 (05) :1259-1266
[3]   Synergistic interactions between tamoxifen and trastuzumab (Herceptin) [J].
Argiris, A ;
Wang, CX ;
Whalen, SG ;
DiGiovanna, MP .
CLINICAL CANCER RESEARCH, 2004, 10 (04) :1409-1420
[4]   HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: A southwest oncology group study [J].
Arpino, G ;
Green, SJ ;
Allred, DC ;
Lew, D ;
Martino, S ;
Osborne, CK ;
Elledge, RM .
CLINICAL CANCER RESEARCH, 2004, 10 (17) :5670-5676
[5]   ONCOGENE AMPLIFICATION AND PROGNOSIS IN BREAST-CANCER - RELATIONSHIP WITH SYSTEMIC TREATMENT [J].
BERNS, EMJJ ;
FOEKENS, JA ;
VANSTAVEREN, IL ;
VANPUTTEN, WLJ ;
DEKONING, HYWCM ;
PORTENGEN, H ;
KLIJN, JGM .
GENE, 1995, 159 (01) :11-18
[6]   Biological response to hormonal manipulation in oestrogen receptor positive ductal carcinoma in situ of the breast [J].
Boland, GP ;
Mckeown, A ;
Chan, KC ;
Prasad, R ;
Knox, WF ;
Bundred, NJ .
BRITISH JOURNAL OF CANCER, 2003, 89 (02) :277-283
[7]   ERBB2 AMPLIFICATION IS ASSOCIATED WITH TAMOXIFEN RESISTANCE IN STEROID-RECEPTOR POSITIVE BREAST-CANCER [J].
BORG, A ;
BALDETORP, B ;
FERNO, M ;
KILLANDER, D ;
OLSSON, H ;
RYDEN, S ;
SIGURDSSON, H .
CANCER LETTERS, 1994, 81 (02) :137-144
[8]   c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases [J].
Carlomagno, C ;
Perrone, F ;
Gallo, C ;
DeLaurentiis, M ;
Lauria, R ;
Morabito, A ;
Pettinato, G ;
Panico, L ;
DAntonio, A ;
Bianco, AR ;
DePlacido, S .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (10) :2702-2708
[9]   CORRELATION OF HER-2/NEU AMPLIFICATION WITH EXPRESSION AND WITH OTHER PROGNOSTIC FACTORS IN 1103 BREAST CANCERS [J].
CIOCCA, DR ;
FUJIMURA, FK ;
TANDON, AK ;
CLARK, GM ;
MARK, C ;
LEECHEN, GJ ;
POUNDS, GW ;
VENDELY, P ;
OWENS, MA ;
PANDIAN, MR ;
MCGUIRE, WL .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1992, 84 (16) :1279-1282
[10]   Prognostic value of HER-23/neu and p53 expression in node-positive breast cancer.: HER-2/neu effect on adjuvant tamoxifen treatment [J].
Climent, MA ;
Seguí, MA ;
Peiró, G ;
Molina, R ;
Lerma, E ;
Ojeda, B ;
López-López, JJ ;
Alonso, C .
BREAST, 2001, 10 (01) :67-77